Invasive BCI Devices

The clinical BCI landscape in 2025-2026 is dominated by two companies that have moved from feasibility studies to commercial-track trials: Neuralink (intracortical) and Synchron (endovascular). They represent opposite bets on the surgical risk / signal quality tradeoff, both validated by clinical milestones in this period.

Neuralink PRIME Study

Neuralink's N1 implant is a coin-sized device with 1,024 flexible electrode threads inserted into the motor cortex by a custom surgical robot. The PRIME (Precisely Robotically Implanted Brain-Computer Interface) study is the first-in-human trial.

Current status (as of early 2026):

• ~20 patients implanted
• Demonstrated capabilities: cursor control, typing, gaming through thought
• FDA breakthrough device designation granted
• International expansion: UK and UAE clinical trials announced
• Patients report using the device for daily activities

Technical approach: Intracortical electrode arrays record single-unit spiking activity — the highest-fidelity neural signal available. The robotic surgical system enables precision placement of ultra-thin flexible electrodes to minimize tissue damage. The N1 chip performs on-device signal processing and wireless transmission.

Key challenge: Long-term electrode biocompatibility. Brain tissue responds to foreign objects with glial scarring, which progressively degrades signal quality over years. Long-term (5-10 year) data does not yet exist for the N1 implant at scale.

Synchron Stentrode

Synchron's Stentrode uses an endovascular delivery approach — the device is a self-expanding stent with embedded electrodes, delivered through the jugular vein and lodged in the superior sagittal sinus, adjacent to the motor cortex. No craniotomy required.

Feasibility trial results (12-month):

• 6 patients with severe motor paralysis
• Primary safety and efficacy endpoint met
• No serious adverse events related to the device
• First FDA-approved permanently implanted BCI to meet a feasibility primary endpoint
• $200M Series D raised for pivotal trials (2026)
• Market entry projected 2028-2029 contingent on pivotal trial success

Technical approach: Records local field potentials (LFPs) from cortical vasculature. Signal quality is intermediate — better than surface EEG but lower than intracortical arrays. Demonstrated application: iPad control (messaging, web browsing, email) via thought.

Competitive advantage: The absence of craniotomy dramatically expands patient eligibility. Patients who cannot undergo or choose not to risk brain surgery could access a Stentrode-class device. This positions Synchron for a substantially larger addressable market than intracortical approaches.

Other Devices in Pipeline

The clinical review (Deng et al. 2025) notes other BCI devices at various trial stages:

• Neuropace RNS — closed-loop cortical stimulation for epilepsy; FDA cleared; in clinical use
• Abbott Infinity DBS — closed-loop DBS for Parkinson's, using LFP biomarkers
• Precision Neuroscience Layer 7 — minimally invasive intracortical interface (surface array, not penetrating); early trials
• Paradromics Connexus — high-bandwidth cortical interface; preclinical

Regulatory Landscape

Both intracortical and endovascular BCIs face multi-phase FDA regulatory pathways:

• IDE (Investigational Device Exemption) → Feasibility trial → Pivotal trial → PMA (Premarket Approval)
• FDA breakthrough device designation (Neuralink) accelerates review timelines
• Post-market surveillance requirements are substantial given the novel technology
• International expansion requires country-specific regulatory approvals (MHRA for UK, etc.)

Key Claims

• Neuralink PRIME: ~20 patients with functional thought-controlled computing — Cursor, typing, gaming demonstrated across real patients in real use. Evidence: strong (Neuralink PRIME)
• Synchron Stentrode: first FDA-approved implanted BCI to meet feasibility primary endpoint — 12-month safety + efficacy data from 6 patients. No-craniotomy approach validated clinically. Evidence: strong (Synchron Stentrode)
• Endovascular approach targets broader patient population than intracortical — No craniotomy requirement means more patients qualify; lower risk-benefit threshold. Evidence: moderate (Synchron Stentrode)
• Flexible neural interfaces are key enabling technology across invasiveness tiers — Flexible substrates reduce tissue damage, improve chronic biocompatibility. Evidence: moderate (Clinical Review)

Benchmarks & Data

• Neuralink PRIME: ~20 patients (Feb 2026) (Neuralink PRIME)
• Synchron feasibility: 6 patients, 12 months, primary endpoint met (Synchron Stentrode)
• Synchron Series D: $200M for pivotal trials (Synchron Stentrode)
• Projected market entry: 2028-2029 (Synchron) (Synchron Stentrode)

Open Questions

• What is the 5-10 year electrode stability data for intracortical arrays?
• Can Stentrode-class devices achieve higher bandwidth with improved electrode designs?
• How will commercial pricing and insurance reimbursement shape patient access?
• What happens when implanted devices need hardware updates or software patches years post-implantation?
• How do Neuralink and Synchron data compare on quality-of-life outcomes?

Related Concepts

• Invasive vs. Non-Invasive BCI — The modality framework these devices occupy
• BCI Clinical Applications — The conditions these devices target
• BCI Signal Acquisition — Technical details of intracortical vs. endovascular recording

Changelog

• 2026-04-14 — Created from Neuralink PRIME report, Synchron feasibility trial report, and ScienceDirect clinical review. Covers clinical trial status, technical approaches, regulatory landscape, and competitive positioning.